Dr. Nolwenn M. Dheilly
nmdheilly.bsky.social
PhD, HDR, Research Director @ Institut Pasteur Paris. The pathogen Discovery Lab uses Metagenomics to discover novel viruses for improved diagnostics, therapeutics and prevention. #virology #NGS #microbiome #emergence #parasite #holobiont #surveillance
👤 Joined on 20 November 2024
303
Followers
655
Following
13
Total Posts
📜 Kullanıcı Geçmişi
- 20 Kas 2024, 05:01
🎉 Bluesky'e katıldı - İlk kullanıcı adı:
@nmdheilly.bsky.social
🚫 Blokladığı Kullanıcılar
❤️ Beğendiği Gönderiler
New preprint led by our MSc student Wenye Li!! 🎉 @systemsvirology.bsky.social What we find is a historic genetic interplay between sarbecoviruses and their horseshoe bat hosts' ACE2 receptor! 🦇 🧵... www.biorxiv.org/content/10.1...
Show Post
CREID was using a "One Health" approach to perform basic research into all the pathogens out there to gain an understanding of their emergence, spread, and evolution - as well as their pandemic potential, including novel ones. Again, critically important. And like AViDD, CREID was canceled.
Show PostAViDD was using a similar approach, but this time focused on developing novel anti-viral drugs, with a focus on broad-spectrum drugs. Similar to ReVAMPP, this would give us new drugs against existing pathogens, as well as a new arsenal for emerging ones. AViDD was canceled.
Show PostThat means that not only would we have new countermeasures against existing, and highly consequential, pathogens, but we'd be able to pivot existing platforms should a novel species within one of those families emerge. This is extremely prudent, and frankly, a clever way of doing it.
Show PostReVAMPP is focused on developing novel vaccines and monoclonals for a whole range of high consequence pathogens using a "prototype" approach. In essence, for each key virus family, select a few prototype viruses and develop new countermeasures against those.
Show Post